Tìm theo
Procarbazine
Các tên gọi khác (12 ) :
  • 1-Methyl-2-(P-(isopropylcarbamoyl)benzyl)hydrazine
  • 2-(P-Isopropylcarbamoylbenzyl)-1-methylhydrazine
  • 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide
  • N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide
  • N-4-Isopropylcarbamoylbenzyl-n'-methylhydrazine
  • N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide
  • N-Isopropyl-alpha-(2-methylhydrazino)-P-toluamide
  • N-Isopropyl-P-(2-methylhydrazinomethyl)-benzamide
  • P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
  • Procarbazin
  • Procarbazina
  • Procarbazinum
Thuốc điều trị ung thư
Thuốc Gốc
Small Molecule
CAS: 671-16-9
ATC: L01XB01
ĐG : AAIPharma Inc. , http://www.aaipharma.com
CTHH: C12H19N3O
PTK: 221.2988
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C12H19N3O
Phân tử khối
221.2988
Monoisotopic mass
221.152812245
InChI
InChI=1S/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)
InChI Key
InChIKey=CPTBDICYNRMXFX-UHFFFAOYSA-N
IUPAC Name
4-[(2-methylhydrazin-1-yl)methyl]-N-(propan-2-yl)benzamide
Traditional IUPAC Name
procarbazine
SMILES
CNNCC1=CC=C(C=C1)C(=O)NC(C)C
Độ tan chảy
223 °C
Độ hòa tan
1420 mg/L
logP
0.06
logS
-3
pKa (strongest acidic)
15.03
pKa (Strongest Basic)
5.6
PSA
53.16 Å2
Refractivity
86.98 m3·mol-1
Polarizability
25.88 Å3
Rotatable Bond Count
5
H Bond Acceptor Count
3
H Bond Donor Count
3
Physiological Charge
0
Number of Rings
1
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Procarbazine is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Procarbazine is cell-phase specific for the S phase of cell division.
Cơ Chế Tác Dụng : An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. [PubChem] The precise mode of cytotoxic action of procarbazine has not been clearly defined. There is evidence that the drug may act by inhibition of protein, RNA and DNA synthesis. Studies have suggested that procarbazine may inhibit transmethylation of methyl groups of methionine into t-RNA. The absence of functional t-RNA could cause the cessation of protein synthesis and consequently DNA and RNA synthesis. In addition, procarbazine may directly damage DNA. Hydrogen peroxide, formed during the auto-oxidation of the drug, may attack protein sulfhydryl groups contained in residual protein which is tightly bound to DNA.
Dược Động Học :
▧ Absorption :
Procarbazine is rapidly and completely absorbed.
▧ Metabolism :
Procarbazine is metabolized primarily in the liver and kidneys. The drug appears to be auto-oxidized to the azo derivative with the release of hydrogen peroxide. The azo derivative isomerizes to the hydrazone, and following hydrolysis splits into a benzylaldehyde derivative and methylhydrazine. The methylhydrazine is further degraded to CO2 and CH4 and possibly hydrazine, whereas the aldehyde is oxidized to N-isopropylterephthalamic acid, which is excreted in the urine.
▧ Half Life :
10 minutes
Độc Tính : LD50=785 mg/kg (orally in rats)
Chỉ Định : For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.
Tương Tác Thuốc :
  • Bezafibrate MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like procarbazine.
  • Brimonidine MAO Inhibitors like procarbazine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated.
  • Buprenorphine Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like procarbazine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects.
  • Desvenlafaxine Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
  • Digoxin The antineoplasic agent decreases the effect of digoxin
  • Methotrexate Increased nephrotoxicity with this combination
  • Milnacipran Increase serotonin levels. Combination therapy is contraindicated.
  • Tetrabenazine Tetrabenazine may increase the adverse/toxic effects of Procarbazine. Concomitant therapy is contraindicated.
  • Tolcapone Tolcapone and Procarbazine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects.
  • Tramadol Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Procarbazine.
  • Tranylcypromine Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
  • Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
  • Trazodone Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Trimipramine Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis.
  • Venlafaxine Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided.
  • Zolmitriptan The MAO inhibitor, procarbazine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing procarbazine are contraindicated.
Liều Lượng & Cách Dùng : Capsule - Oral
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Matulane 50 mg capsule
    Giá bán buôn : USD >55.68
    Đơn vị tính : capsule
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Indicarb
  • Công ty :
    Sản phẩm biệt dược : Matulane
  • Công ty :
    Sản phẩm biệt dược : Natulan
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01168
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=4915
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507706
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07402
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00478
ChemSpider
http://www.chemspider.com/Chemical-Structure.4746.html
PharmGKB
http://www.pharmgkb.org/drug/PA451112
Wikipedia
http://en.wikipedia.org/wiki/Procarbazine
RxList
http://www.rxlist.com/cgi/generic3/procarb.htm
Drugs.com
http://www.drugs.com/cdi/procarbazine.html
... loading
... loading